Granada, España
Santander, España
Elche, España
Pamplona, España
Madrid, España
San Cristóbal de La Laguna, España
Sevilla, España
Ciudad Real, España
Salamanca, España
Fuenlabrada, España
Ferrol, España
Alicante, España
Palencia, España
Arganda del Rey, España
Pontevedra, España
Oviedo, España
Background The optimal chemotherapy backbone for HER2-negative advanced esophagogastric cancer, either in combination with targeted therapies or as a comparator in clinical trials, is uncertain. The subtle yet crucial diferences in platinumbased regimens' safety and synergy with combination treatments need consideration.
Methods We analyzed cases from the AGAMENON–SEOM Spanish registry of HER2-negative advanced esophagogastric adenocarcinoma treated with platinum and fuoropyrimidine from 2008 to 2021. This study focused exclusively on patients receiving one of the four regimens: FOLFOX (5-FU and oxaliplatin), CAPOX (capecitabine and oxaliplatin), CP (capecitabine and cisplatin) and FP (5-FU and cisplatin). The aim was to determine the most efective and tolerable platinum and fuoropyrimidine-based chemotherapy regimen and to identify any prognostic factors.
Results Among 1293 patients, 36% received either FOLFOX (n=468) or CAPOX (n=466), 20% CP (n=252), and 8% FP (n=107). FOLFOX signifcantly increased PFS (progression free survival) compared to CP, with a hazard ratio of 0.73 (95% CI 0.58–0.92, p=0.009). The duration of treatment was similar across all groups. Survival outcomes among regimens were similar, but analysis revealed worse ECOG–PS (Eastern Cooperative Oncology Group–Performance Status),>2 metastatic sites, bone metastases, hypoalbuminemia, higher NLR (neutrophil-to-lymphocyte ratio), and CP regimen as predictors of poor PFS. Fatigue was common in all treatments, with the highest incidence in FOLFOX (77%), followed by FP (72%), CAPOX (68%), and CP (60%). Other notable toxicities included neuropathy (FOLFOX 69%, CAPOX 62%), neutropenia (FOLFOX 52%, FP 55%), hand–foot syndrome in CP (46%), and thromboembolic events (FP 12%, CP 11%).
Conclusions FOLFOX shown better PFS than CP. Adverse efects varied: neuropathy was more common with oxaliplatin, while thromboembolism was more frequent with cisplatin.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados